CN103432632A - Temperature-sensitive gel composition and preparation method thereof - Google Patents
Temperature-sensitive gel composition and preparation method thereof Download PDFInfo
- Publication number
- CN103432632A CN103432632A CN2013104197847A CN201310419784A CN103432632A CN 103432632 A CN103432632 A CN 103432632A CN 2013104197847 A CN2013104197847 A CN 2013104197847A CN 201310419784 A CN201310419784 A CN 201310419784A CN 103432632 A CN103432632 A CN 103432632A
- Authority
- CN
- China
- Prior art keywords
- temperature
- thermosensitive
- situ gel
- gel
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000002378 acidificating effect Effects 0.000 claims abstract description 10
- 229920001993 poloxamer 188 Polymers 0.000 claims description 23
- 229940044519 poloxamer 188 Drugs 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
- 235000003704 aspartic acid Nutrition 0.000 claims description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- 238000011065 in-situ storage Methods 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 229960003511 macrogol Drugs 0.000 claims description 6
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 4
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229940085675 polyethylene glycol 800 Drugs 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 150000001510 aspartic acids Chemical class 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract description 29
- 210000004204 blood vessel Anatomy 0.000 abstract description 13
- 230000002439 hemostatic effect Effects 0.000 abstract description 9
- 229920001992 poloxamer 407 Polymers 0.000 abstract description 2
- 229940044476 poloxamer 407 Drugs 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000000017 hydrogel Substances 0.000 description 35
- 239000000499 gel Substances 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 230000007704 transition Effects 0.000 description 17
- 230000023597 hemostasis Effects 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003708 ampul Substances 0.000 description 9
- 229920001983 poloxamer Polymers 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 208000005189 Embolism Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 229960000502 poloxamer Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- -1 biogum Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229920002511 Poloxamer 237 Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010071229 Procedural haemorrhage Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to a temperature-sensitive gel composition containing poloxamer 407, acidic amino acid, polyethylene glycol and water and a preparation method thereof. In a surgical operation, the temperature-sensitive gel composition is injected into a blood vessel to form a gel suppository so as to realize a hemostatic effect.
Description
Technical field
The invention belongs to field of medical technology, relate to a kind of intravenous thermosensitive in situ gel, there is not damaged, advantage simply and fast.
Background technology
Nearly all surgical operation all can't be avoided intraoperative hemorrhage, and along with the appearance of scientific and technological development and some novel hemostatic materials and equipment, in surgical operation, hemostatic technique has also produced revolutionary development.Hemostasis is one of core of essential surgical skills technology, the surgical procedures at any position of human body almost relates to hemorrhage and hemostasis bar none, hemostatic technique has been developed into the technical system of the numerous and complicated under the modern surgery condition by simple apparatus hemostasis measure of past, mainly comprise that Interventional hemostasis measure, physics and chemistry hemostasis measure and hemostatic for external use fibres albumen viscose glue are several.
The Interventional hemostatic treatment refers in conduit, entry needle, air bag or other related equipments importing internal organs that will treat use under endoscope, ultrasonic, CT or x-ray monitor, and give localized pulverization or inject the plug treatments such as haemostatic medicament, biogum, chemical glue, or import the chemical factors such as high frequency electric, laser, microwave, reach the purpose for the treatment of hemorrhagic focus.
Physics and chemistry hemostasis physics and chemistry Hemostasis is long-standing, and along with the progress of modern science and technology, more more superior hemostatic techniques arise at the historic moment, as methods such as high-frequency electrocoagulation hemostasis, laser hemostasis, microwave bleeding and thermal hemostasis.
Hemostatic for external use fibres albumen viscose glue technical system comprises the application of some microfilament fiber collagen hemorrhages, oxidized cellulose and oxidized regenerated cellulose.
For the process of surgical hemostasis, a kind of not damaged, simply and fast Hemostasis is maximum advantage.F127 with temperature-sensing property has these potential qualities.Raymond etc. utilize the Thermo-sensitive of F127 to be applied to temporary tremulous pulse plug plug in bypass operation of coronary artery first.The up-to-date a kind of product gone out of match Norfin, Inc
it is a kind of good solution, it is that poloxamer188 thermosensitive hydrogel hemostatic technique is applied to commercially produced product, utilized poloxamer188, at room temperature and low temperature state, be liquid, being injected into after human vas temperature goes up and rises to 37 ℃ of left and right, will form a gel plug, thereby stop blood flow.That this method has is painless, control fast, at any time and the advantage such as nontoxic, and the market application is very wide.
clinical verification is under the prerequisite of injured blood vessel not, makes the blood flow volume that flows to operative region be down to minimum effect.Some hemostasis instruments commonly used (as mosquito forceps or elastic tape) can not guarantee the operative region depletion of blood and may destroy blood vessel.
to the temperature altitude sensitivity, when room temperature, be liquid, and it is solid-state to become gel when high temperature.After being injected into blood vessel,
form and take the gel embolism that shape of blood vessel is mould, can stop blooding and reach 15 minutes.After vascular suture, blood vessel embolism can be in 15 minutes automatic dissolving.If need make thromboembolism dissolve fast, only need be on blood vessel cold compress or inject cold normal saline, thromboembolism will soon disappear, the blood flow immediate recovery of operative site is normal.
The patent 00107386.9 of China provides a kind of vascular occlusive agent and process of preparing thereof.It is to adopt poloxamer188 and a certain amount of medicine, normal saline.The suppository of preparation.Have stability better, can high-temperature sterilization, plug plug effect is better, can carry cancer therapy drug and other medicines, can be widely used in the plug plug chemotherapy of tumor; Alimentary canal inflammation, ulcer etc. are hemorrhage.
Summary of the invention
The invention provides compositions and the preparation method of the thermosensitive in situ gel that a kind of clotting time is more durable, particularly, to adopt Polyethylene Glycol, poloxamer188 and a kind of acidic amino acid to form, the phase transition temperature that this gel adopts Polyethylene Glycol to regulate thermosensitive hydrogel, after this liquid gel intravasation, promptly form a thromboembolism, stop flowing of blood; Added acidic amino acid to change the electric charge of poloxamer188, made the gel plug holdup time in vivo of formation longer, more than having reached 30min, after operation finishes, only needed the suitable cooling blood vessel embolism of the mode district of employing, it is normal that blood flow will recover very soon.
Thermosensitive hydrogel of the present invention is to adopt Polyethylene Glycol, poloxamer188, water and acidic amino acid to form, specifically this gel adopts the phase transition temperature that Polyethylene Glycol has been regulated thermosensitive hydrogel, by amino acid change the electric charge of gel, make it to be easier to form gel plug holdup time in vivo longer, thereby extended the time of the blood flow retardance of blood vessel, for the better time of being provided smoothly of operation ensures, after operation is accepted, overlay on area vasculosa with ice or cold object, blood flow will recover at once.
Thisly to heat sensitive and there is the liquid gel that biocompatibility is nontoxic, when it is injected in blood vessel, a gel plug can be formed, blood flow can be temporarily stoped.This gel plug is by cooling or or can dissolve rapidly after dozens of minutes under autonomous state.Once, after dissolving, because the concentration of poloxamer is too low, gel plug just can not be recovered.
Poloxamer is that a kind of nontoxic, non-irritating adjuvant is widely used, because the commercial adjuvant of the difference of molecular weight has Pluronic/Lutrol F 44, PLURONICS F87, poloxamer 237, poloxamer 388 and poloxamer188.Poloxamer188 (Poloxamer407, P407) be the block copolymer of polyoxyethylene and polyoxypropylene, by approximately 70% ethylene oxide and 30% propylene oxide form, molecular weight is 9840～14600, and poloxamer188 has the solidifying character of special reverse hot glue, is liquid during low temperature, become gel under body temperature, advantages such as its toxicity is low, and zest is little, good biocompatibility and receiving much concern.
In the present invention, poloxamer is as the material of thermosensitive hydrogel, and its consumption is 10～35%, and the consumption of further optimizing is between 15～35%.
The adjusting of the phase transition temperature of thermosensitive hydrogel is to control key of the present invention, in the present invention, except the concentration of controlling poloxamer188, adopted in addition the combination of Polyethylene Glycol and acidic amino acid regulate gel electrically and phase transition temperature.
Polyethylene Glycol is macromolecular material, by intermolecular hydrogen bond and poloxamer188 combination, can obviously improve phase transition temperature, makes poloxamer can compare independent use when relative low concentration, has improved phase transition temperature.
The Polyethylene Glycol of selecting in the present invention is lower molecular weight, and the Polyethylene Glycol adopted through screening is Macrogol 600, and it is the most suitable that Polyethylene Glycol 800 and cetomacrogol 1000 are regulated the poloxamer188 Phase-change Problems.
Adding of Polyethylene Glycol successively do not require.For better and poloxamer188 mix, mode is first to add aminoacid or Polyethylene Glycol in water preferably, stirring and dissolving, and then add the poloxamer188 stirring and dissolving.
The control of temperature has crucial effect for preparation process, because temperature raises, the meeting that poloxamer188 dissolves in water is slack-off, and viscosity increases simultaneously, in solution, can produce a large amount of foams, is unfavorable for the preparation of gel.Of the present invention be that process for preparation is controlled at the temperature of solution below 10 ℃, whole like this process is solution state, can make so the abundant mix homogeneously of aminoacid, Polyethylene Glycol and poloxamer188, is conducive to the performance of gelation.The present invention is controlled at the temperature of equipment below 10 ℃ at preparation, stirring, filtration and pouring process, and ambient temperature is controlled at 20 ℃ of left and right.
Macrogol 600, Polyethylene Glycol 800 and cetomacrogol 1000 can be a kind of Polyethylene Glycol, it can be also its combination of any two or three, according to the molecular weight difference, consumption can play the phase transition temperature of better adjusting thermosensitive hydrogel in 2～20% (weight ratios), by test, according to the difference of molecular weight polyethylene glycol and the temperature of required adjusting, the amount that Polyethylene Glycol is further optimized is 3～8% (weight ratios).
Acidic amino acid is containing usually containing 1 amino and 2 carboxyls, isoelectric point, IP is between 2.8～3.2, especially aspartic acid (Asp) and glutamic acid (Glu), this two seed amino acid joins in aqueous solution, with positive charge, utilize in the present invention it to change the electrical of thermosensitive hydrogel, make gel systems after forming gel plug, can in the blood vessel standard, maintain the longer time.Certainly, after blood vessel local cooling, the gel plug of formation becomes fast the liquid gel plug and disappears, and also immediate recovery is mobile normally for blood simultaneously.The aminoacid that the present invention adds can be the combination of any proportioning of any one or two kinds of aspartic acid and glutamic acid.
The consumption of aspartic acid has the longer persistent period at 1～20% (weight ratio) thermosensitive hydrogel in the formation gel plug later, and preferably the amount of aspartic acid is between 2～7%.
The amount of glutamic acid is in the persistent period preferably that has of 1～15% (weight ratio), and thermosensitive hydrogel has the longer persistent period in the formation gel plug later, and preferably the amount of glutamic acid is 1～5%.
Two kinds of two kinds of acidic amino acid glutamic acid and aspartic acids also arbitrarily proportioning be used in combination.Preferred consumption is 1-12% (weight ratio).
The optimum pH of thermosensitive hydrogel of the present invention is 3～5, can adopt the aqueous solution of two kinds of acidic amino acids that the present invention relates to or sodium hydroxide solution adjustment to reach the acidity needed, and further preferred pH is 3.5～4.5.
Thermosensitive hydrogel of the present invention is liquid when low temperature, during use, need quiet notes to bring into play the block blood flow effect in blood vessel, so need to carry out aseptic and apyrogeneity processing to it, the method of sterilizing has adopted conventional autoclaving, adopt temperature and condition to be: 121 ℃ keep 15min or 115 ℃ to keep 30 minutes, such condition can be removed the antibacterial in thermosensitive hydrogel, makes it to be suitable for intravenous injection.Also can adopt the method for ray sterilizing to remove the antibacterial in thermosensitive hydrogel.
For the pyrogen of introducing in aminoacid, Polyethylene Glycol, poloxamer188, water and environment in thermosensitive hydrogel, the present invention adopts the method for activated carbon adsorption to remove, specifically a certain amount of active carbon is joined in the thermosensitive hydrogel prepared, mechanical agitation 15-30min, after filtration, thermosensitive hydrogel is packed into after ampulla sealing or injector package and carried out sterilizing.
In thermosensitive hydrogel, the removal of pyrogen also can adopt the methods such as high-temperature heating, ultrafiltration, and these methods are the pharmacy worker and know.
Must hide in chamber and be cooled in advance below 10 ℃ in refrigerator and cooled when thermosensitive hydrogel prepared by the present invention is used, such temperature can guarantee that the state of thermosensitive hydrogel is liquid, thereby be injected into formation gel plug in body, reaches anastalsis.
The present invention can make restoration of blood flow with the position of ice-cold deposited injection thermosensitive hydrogel after preparing the thermosensitive hydrogel application after operation completes, and also can inject cold normal saline at injection thermosensitive hydrogel position simultaneously and make the fast quick-recovery of blood flow.
The specific embodiment
Embodiment 1
Preparation method,
1. the poloxamer188 of recipe quantity is dissolved in water, adds recipe quantity glutamic acid and Macrogol 600, stirring and dissolving, make thermosensitive hydrogel liquid. control 5 ℃ of temperature.
2. employing glutamic acid aqueous solution or sodium hydroxide solution add the pH regulator of thermosensitive hydrogel liquid 0.1% active carbon to 4.0., stir 15min, control 8 ℃ of temperature.
3. filter, active carbon is removed, control 5 ℃ of temperature.
4. will be filled in ampulla or the pre-syringe of loading, content 2-10ml, the temperature of controlling filling machine fluid reservoir, system and environment is 10 ℃.
5. ampulla is sealed.
6.121 ℃ sterilizing 15 minutes.
Embodiment 2
Preparation method,
1. the poloxamer188 of recipe quantity is dissolved in water, adds recipe quantity aspartic acid and Macrogol 600, stirring and dissolving, make thermosensitive hydrogel liquid. control 5 ℃ of temperature.
2. employing aspartic acid aqueous solution or sodium hydroxide solution add the pH regulator of thermosensitive hydrogel liquid 0.1% active carbon to 4.0., stir 15min, control 8 ℃ of temperature.
3. filter, active carbon is removed, control 5 ℃ of temperature.
4. will be filled in the syringe of pre-filling, content 2-10ml, the temperature of controlling filling machine fluid reservoir, system and environment is 10 ℃.
5.121 ℃ sterilizing 15 minutes.
Embodiment 3
1. the poloxamer188 of recipe quantity is dissolved in water, adds recipe quantity glutamic acid, aspartic acid and Polyethylene Glycol 800, stirring and dissolving, make thermosensitive hydrogel liquid. control 5 ℃ of temperature.
2. employing aspartic acid aqueous solution or sodium hydroxide solution add the pH regulator of thermosensitive hydrogel liquid 0.1% active carbon to 4.0., stir 15min, control 8 ℃ of temperature.
3. filter, active carbon is removed, control 5 ℃ of temperature.
4. will be filled in ampulla, content 5-20ml, the temperature of controlling filling machine fluid reservoir, system and environment is 10 ℃.
5. ampulla is sealed.
6.121 ℃ sterilizing 15 minutes.
Embodiment 5
Preparation method,
1. the poloxamer of recipe quantity is dissolved in water, adds recipe quantity aspartic acid and cetomacrogol 1000, stirring and dissolving, make thermosensitive hydrogel liquid. control 5 ℃ of temperature.
2. employing aspartic acid aqueous solution or sodium hydroxide solution add the pH regulator of thermosensitive hydrogel liquid 0.1% active carbon to 4.0., stir 15min, control 8 ℃ of temperature.
3. filter, active carbon is removed, control 5 ℃ of temperature.
4. in fill ampulla, content 2-10ml, the temperature of controlling filling machine fluid reservoir, system and environment is 10 ℃.
5. ampulla is sealed.
6.121 ℃ sterilizing 15 minutes.
Embodiment 6
Preparation method:
1. the poloxamer188 of recipe quantity is dissolved in water, adds recipe quantity glutamic acid and Macrogol 600, stirring and dissolving, make thermosensitive hydrogel liquid. control 5 ℃ of temperature.
2. employing glutamic acid aqueous solution or sodium hydroxide solution add the pH regulator of thermosensitive hydrogel liquid 0.1% active carbon to 4.0., stir 15min, control 8 ℃ of temperature.
4. will be filled in ampulla or the pre-syringe of loading, content 2-10ml, the temperature of controlling filling machine fluid reservoir, system and environment is 8 ℃.
5. ampulla is sealed.
6.300 ℃ heating 120 minutes.
Test implementation example 1
The mensuration of the phase transition temperature of gel
Viscosimetry is measured, and sample is placed in to water-bath, and the rotating cylinder of viscosity apparatus is placed in to sample, temperature is made as to 10,15,20,25,30,35,40,45 ℃ respectively, every temperature keeps starting to measure viscosity after 5min, matched curve, the phase transition temperature of investigation different formulations.
Table 1. is commercially available to be contrasted with the embodiment phase transition temperature
| ? | The listing formula | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Phase transition temperature (℃) | 31.5 | 29.3 | 28.9 | 27.8 | 26.8 | 25.9 |
Adopt embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5, contrast is according to external listing product.Measure the phase transition temperature of thermosensitive hydrogel.Result can find out that the phase transition temperature of the embodiment of the present invention is all lower than Comparative Examples, illustrates that being easier to the present invention respectively forms gel plug in vivo and be beneficial to hemostasis.
Adopt the gel of preparation in embodiment 4, prepare 6 batches, by upper method, investigate phase transition temperature, the visible phase transition temperature difference of result is very little, within the acceptable range.
The differences between batches of table 2. embodiment 4 phase transition temperatures
| Test number (TN) | 1 | 2 | 3 | 4 | 5 | 6 |
| Phase transition temperature (℃) | 28.1 | 27.4 | 28.9 | 27.8 | 27.3 | 26.8 |
Test implementation example 2
To the femoral artery of new zealand white rabbit, first with the vascular clamp folder, close about 1cm long femoral artery or ventral aorta, then with microsyringe, a certain amount of gel is injected in this section arterial lumen; The other end loses blood flow immediately, writing time, the time of observing restoration of blood flow.
The contrast of table 3. thermosensitive hydrogel bleeding stopping period
| ? | The listing formula | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Clotting time (min) | 19.5 | 39 | 45.5 | 40.5 | 48.0 | 47.5 |
With external listing kind, compare, the clotting time of the embodiment of the present invention 1, embodiment 2, embodiment 3, embodiment 4 and embodiment 5 is all apparently higher than commercially available prod.Bleeding stopping period of the present invention is more than 2 times of commercially available prod, can be so more enforcement time of winning of smooth operation.
Claims (8)
1. a thermosensitive in situ gel compositions, contain poloxamer188, acidic amino acid and low-molecular-weight Polyethylene Glycol and water.
2. thermosensitive in situ gel claimed in claim 1, wherein adopt poloxamer188 as temperature-sensitive material, and preferred consumption is 15%～35% (weight ratio).
3. the described thermosensitive in situ gel of claim 2, contain glutamic acid, and its preferred consumption is 2～7% (weight ratios).
4. the described thermosensitive in situ gel of claim 2, contain aspartic acid, and its preferred consumption is 1～5% (weight ratio).
5. the described thermosensitive in situ gel of claim 2, the combination that contains two kinds of acidic amino acid glutamic acid and aspartic acids.Preferred consumption is 1～12% (weight ratio).
6. claim 3,4,5 described thermosensitive in situ gel, also contain Macrogol 600, the combination of Polyethylene Glycol 800 and cetomacrogol 1000 or its arbitrary proportion, and consumption is 3%～8% (weight ratio).
7. thermosensitive in situ gel claimed in claim 6, its pH is 3～4.5, advancing the preferred pH of (weight ratio) step is 3.5～4.5.
8. thermosensitive in situ gel claimed in claim 7, reach for the vein blood vessel injection purpose that occluding vascular stops blooding, and surgical operation is carried out smoothly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310419784.7A CN103432632B (en) | 2013-09-16 | 2013-09-16 | A kind of thermosensitive in situ gel compositions and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310419784.7A CN103432632B (en) | 2013-09-16 | 2013-09-16 | A kind of thermosensitive in situ gel compositions and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103432632A true CN103432632A (en) | 2013-12-11 |
| CN103432632B CN103432632B (en) | 2015-11-25 |
Family
ID=49686408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310419784.7A Active CN103432632B (en) | 2013-09-16 | 2013-09-16 | A kind of thermosensitive in situ gel compositions and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103432632B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104353108A (en) * | 2014-09-29 | 2015-02-18 | 南京康玻斯医药科技有限公司 | Injection applied to blood vessel anastomosis and endovascular occlusion |
| CN106581737A (en) * | 2017-01-06 | 2017-04-26 | 哈尔滨鼓润生物技术有限公司 | Hemostasis composition and preparing method thereof |
| CN107496442A (en) * | 2017-08-25 | 2017-12-22 | 南京斯泰尔医药科技有限公司 | A kind of chlorine dioxide responsive to temperature type spray gel and preparation method thereof |
| CN109432511A (en) * | 2018-12-29 | 2019-03-08 | 常州乐奥医疗科技股份有限公司 | A kind of temperature-sensitive hydrogel and its preparation method and application |
| CN109953940A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of temperature-sensitive hydrogel precursor |
| CN110420175A (en) * | 2019-08-21 | 2019-11-08 | 赣南师范大学 | A kind of injection-type amino acid derivativges small molecule gel rubber material and its application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273860A (en) * | 2000-05-12 | 2000-11-22 | 苏州医学院附属第一医院 | Medicine for treating blood vessel embolism and its preparing process |
| CN101972470A (en) * | 2010-09-13 | 2011-02-16 | 舒泰神（北京）生物制药股份有限公司 | In-situ gel composition for eyes |
| CN102015012A (en) * | 2008-02-29 | 2011-04-13 | 普拉罗美德公司 | Local embolization via heating of thermosensitive polymers |
| WO2012031342A2 (en) * | 2010-09-08 | 2012-03-15 | Universidade Federal Do Rio De Janeiro | Polymer system and method for encapsulating human amylin and agonist analogues, and use thereof; released amylin functional evaluation method |
| CN102525882A (en) * | 2012-02-28 | 2012-07-04 | 上海市肿瘤研究所 | Nanocomposite temperature-sensitive gel and preparation method and application thereof |
| CN102989034A (en) * | 2011-09-10 | 2013-03-27 | 温州医学院 | Hydrogel applicable to neuroanastomosis and preparation method thereof |
| CN102989035A (en) * | 2011-09-10 | 2013-03-27 | 浙江海正药业股份有限公司 | Hydrogel applicable to angiostomy and preparation method thereof |
| CN102988274A (en) * | 2010-09-08 | 2013-03-27 | 上海市肿瘤研究所 | Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof |
-
2013
- 2013-09-16 CN CN201310419784.7A patent/CN103432632B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273860A (en) * | 2000-05-12 | 2000-11-22 | 苏州医学院附属第一医院 | Medicine for treating blood vessel embolism and its preparing process |
| CN102015012A (en) * | 2008-02-29 | 2011-04-13 | 普拉罗美德公司 | Local embolization via heating of thermosensitive polymers |
| WO2012031342A2 (en) * | 2010-09-08 | 2012-03-15 | Universidade Federal Do Rio De Janeiro | Polymer system and method for encapsulating human amylin and agonist analogues, and use thereof; released amylin functional evaluation method |
| CN102988274A (en) * | 2010-09-08 | 2013-03-27 | 上海市肿瘤研究所 | Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof |
| CN101972470A (en) * | 2010-09-13 | 2011-02-16 | 舒泰神（北京）生物制药股份有限公司 | In-situ gel composition for eyes |
| CN102989034A (en) * | 2011-09-10 | 2013-03-27 | 温州医学院 | Hydrogel applicable to neuroanastomosis and preparation method thereof |
| CN102989035A (en) * | 2011-09-10 | 2013-03-27 | 浙江海正药业股份有限公司 | Hydrogel applicable to angiostomy and preparation method thereof |
| CN102525882A (en) * | 2012-02-28 | 2012-07-04 | 上海市肿瘤研究所 | Nanocomposite temperature-sensitive gel and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王丽娟等: "泊洛沙姆407温度敏感型原位凝胶的研究进展", 《中国药学杂志》, vol. 44, no. 4, 28 February 2009 (2009-02-28), pages 245 - 248 * |
| 邓丽娟等: "注射用原位凝胶的研究进展", 《中国抗生素杂志》, vol. 34, no. 9, 30 September 2009 (2009-09-30), pages 513 - 520 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104353108A (en) * | 2014-09-29 | 2015-02-18 | 南京康玻斯医药科技有限公司 | Injection applied to blood vessel anastomosis and endovascular occlusion |
| CN106581737A (en) * | 2017-01-06 | 2017-04-26 | 哈尔滨鼓润生物技术有限公司 | Hemostasis composition and preparing method thereof |
| CN106581737B (en) * | 2017-01-06 | 2019-09-06 | 哈尔滨鼓润生物技术有限公司 | A kind of hemostatic composition and preparation method thereof |
| CN107496442A (en) * | 2017-08-25 | 2017-12-22 | 南京斯泰尔医药科技有限公司 | A kind of chlorine dioxide responsive to temperature type spray gel and preparation method thereof |
| CN109953940A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of temperature-sensitive hydrogel precursor |
| CN109432511A (en) * | 2018-12-29 | 2019-03-08 | 常州乐奥医疗科技股份有限公司 | A kind of temperature-sensitive hydrogel and its preparation method and application |
| CN110420175A (en) * | 2019-08-21 | 2019-11-08 | 赣南师范大学 | A kind of injection-type amino acid derivativges small molecule gel rubber material and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103432632B (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432632B (en) | A kind of thermosensitive in situ gel compositions and preparation method | |
| KR101852718B1 (en) | Kit for pain reduction of incision site after surgical operation | |
| US5951583A (en) | Thrombin and collagen procoagulant and process for making the same | |
| CN105251035A (en) | Perfusive organ hemostasis | |
| US8579882B1 (en) | Cannula system | |
| JP2003500114A (en) | Novel high viscosity embolization composition | |
| AU2015206597B2 (en) | Thermosensitive hydrogel collagenase formulations | |
| JP2010521495A5 (en) | ||
| KR20160089544A (en) | Use of reverse thermosensitive polymers to control biological fluid flow following a medical procedure | |
| KR102192908B1 (en) | Method for manufacturing controlled releasable DDS device using thermosensitive hydrogel | |
| US9932389B2 (en) | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer | |
| CA2913875A1 (en) | Adhesion preventing material | |
| CN114369354B (en) | Injectable hydrogels for vascular embolization | |
| JP3867931B2 (en) | Liquid fibrinogen preparation | |
| WO2020221283A1 (en) | Ethanol hardener and use thereof | |
| CN110215542A (en) | A method of forming the interim obturator of blood vessel | |
| Bernasek et al. | Bloodless surgery by a regional intra-arterial tourniquet during primary and revision THA | |
| CN102989035B (en) | Hydrogel applicable to angiostomy and preparation method thereof | |
| CA2636980A1 (en) | Cannula system | |
| RU2380121C1 (en) | Injection needle and method for using thereof in subcutaneous injections | |
| CN217510566U (en) | Mucous membrane uplift surgical instrument system under endoscope | |
| CN109432511A (en) | A kind of temperature-sensitive hydrogel and its preparation method and application | |
| WO2023177392A1 (en) | Tissue displacement foam | |
| RU2810584C1 (en) | Thermo-controlled composition to stop bleeding temporary | |
| CN114533937B (en) | Biodegradable temperature-sensitive embolic gel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160111 Address after: 210046 room F6, building, No. 9, Nanjing, Jiangsu Patentee after: Nanjing Zeheng Pharmaceutical Science & Technology Co., Ltd. Address before: 210046, room 111, building F6, No. 9 weft Lu, Qixia District, Jiangsu, Nanjing Patentee before: Yao Jing |
|
| CB03 | Change of inventor or designer information |
Inventor after: Yao Jing Inventor after: Zhang Ziqiang Inventor before: Yao Jing |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170419 Address after: 225300 Taizhou City, Jiangsu Province, China Medical City, G23 phase three Patentee after: Jiangsu Ren Kang Biotechnology Co., Ltd. Address before: 210046 room F6, building, No. 9, Nanjing, Jiangsu Patentee before: Nanjing Zeheng Pharmaceutical Science & Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180511 Address after: 210046 room 105, building F7, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee after: Nanjing Staier Medical Technology Co., Ltd. Address before: 225300 G23 building, phase three, China Medical City, Taizhou, Jiangsu Patentee before: Jiangsu Ren Kang Biotechnology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210204 Address after: Jiangsu Beijia Pharmaceutical Co., Ltd., building G43, phase III, China Pharmaceutical City, Taizhou City, Jiangsu Province, 225300 Patentee after: Jiangsu Beijia Pharmaceutical Co.,Ltd. Address before: 210046 room 105, building F7, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee before: NANJING SITAIER MEDICINE TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |